Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Down1.35% Nasdaq Down1.12%

Valeant Pharmaceuticals International, Inc. (VRX)

-NYSE

86.41 Up 0.55(0.64%) 4:05PM EDT|After Hours : 86.51 Up 0.10 (0.12%) 4:49PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 30, 2012Dec 30, 2011Dec 30, 2010
Total Revenue 3,546,626   2,463,450   1,181,237  
Cost of Revenue1,038,516  726,832  405,750  
Gross Profit 2,508,110   1,736,618   775,487  
Operating Expenses
Research Development79,052  65,687  68,311  
Selling General and Administrative750,817  561,486  276,546  
Non Recurring669,671  251,672  320,957  
Others928,885  557,814  219,758  
Total Operating Expenses2,428,425  1,436,659  885,572  
Operating Income or Loss 79,685   299,959   (110,085)
Income from Continuing Operations
Total Other Income/Expenses Net(517)15,082  (41,871)
Earnings Before Interest And Taxes79,168  315,041  (151,956)
Interest Expense473,396  333,041  84,307  
Income Before Tax(394,228)(18,000)(236,263)
Income Tax Expense(278,203)(177,559)(28,070)
Minority Interest -   -   -  
Net Income From Continuing Ops(136,105)122,715  (240,606)
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (116,025) 159,559   (208,193)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (116,025) 159,559   (208,193)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.